Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug...

Published on 22 Nov 2024 on Zacks · via Yahoo Finance

Dosing is expected to begin in the first quarter of 2025. JAZZ Wins Drug Approval Jazz...

Read the rest of the article

Start tracking your investments with Statfolio

We recently published a list of 8 Most Undervalued Pot Stocks to Buy According to Analysts. In th...

Insider Monkey · via Yahoo Finance 28 Nov 2024

On Tuesday, Axsome Therapeutics Inc (NASDAQ:AXSM) said AXS-12 statistically significantly reduced...

Benzinga · via Yahoo Finance 27 Nov 2024

Shares of CDXC have been soaring, and the company still appears to be a decent choice, but what...

Zacks · via Yahoo Finance 23 Nov 2024

Dosing is expected to begin in the first quarter of 2025. JAZZ Wins Drug Approval Jazz...

Zacks · via Yahoo Finance 22 Nov 2024

Following the FDA's approval, Jazz's Ziihera becomes the first dual HER2-targeted bispecific...

Zacks · via Yahoo Finance 22 Nov 2024

The drug zanidatamab-hrii, sold under the brand name Ziihera, is approved for use in previously...

Reuters 21 Nov 2024

Silver Ring Value Partners, an investment management company, released its third-quarter 2024...

Insider Monkey · via Yahoo Finance 19 Nov 2024

On Monday, Baird made a positive adjustment to Jazz Pharmaceuticals ' (NASDAQ:JAZZ) financial...

Investing.com 19 Nov 2024

We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we a...

Insider Monkey · via Yahoo Finance 18 Nov 2024

Jazz Pharmaceuticals PLC (JAZZ) reports robust financial performance with significant growth in k...

GuruFocus.com · via Yahoo Finance 6 Nov 2024